D- and L-2′,3′-didehydro-2′,3′-dideoxy-3′- fluoro-carbocyclic nucleosides: Synthesis, anti-HIV activity and mechanism of resistance

Journal of Medicinal Chemistry

Volumn 50, Issue 8, 2007, Pages 1828-1839

  Wang, Jianing ^a   Jin, Yunho ^a   Rapp, Kimberly L ^b   Schinazi, Raymond F ^b   Chu, Chung K ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 (2,3 DIDEOXY 2,3 DIDEHYDRO 3 FLUORO 6 HYDROXYMETHYLCYCLOPENT 2 ENYL)GUANINE; CARBOVIR; FLUORINE DERIVATIVE; GUANINE DERIVATIVE; GUANOSINE DERIVATIVE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENZYME ACTIVE SITE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR MODEL; MOLECULAR STABILITY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; STRUCTURE ACTIVITY RELATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; GUANINE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; HYDROGEN BONDING; LEUKOCYTES, MONONUCLEAR; MODELS, MOLECULAR; MUTATION; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247212837     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061304k     Document Type: Article

References (34)

1. De Clercq, E. New approaches toward anti-HIV chemotherapy. J. Med. Chem. 2005, 48 (5), 1297-1313.
2. Richman, D. D.; Fischl, M. A.; Grieco, M. H.; Gottlieb, M. S. Volherding, P. A.; Laskin, O. L.; Leedom, J. M.; Groopman, J. E. Mildvan, D.; Hirsch, M. S.; Jackson, G. G.; Durack, D. T.; Phil, D. Lusinoff-Lehrman, S. The AZT collaborative working group. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N. Engl. J. Med. 1987, 317, 192-197.
3. Yarchoan, R.; Pluda, J. M.; Thomas, R. V.; Mitsuya, H.; Brouwers, P.; Wyvill, K. M.; Hartman, N.; Johns, D. G.; Broder, S. Long term toxicity/activity profiles of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990, 336, 526-529.
4. Strames, M. C.; Cheng, Y. C. Celluar, metabolism of 2′,3′- dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 1987, 252, 988-991.
5. Peterson, E. A.; Ramirez-Ronda, C. H.; Hardy, W. D.; Schwartz, R.; Sacks, H. S.; Follansbee, S.; Peterson, D. M.; Cross, A.; Anderson, R. E.; Dunkle, L. M. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J. Infect. Dis. 1995, 171 (Suppl. 2), S131-S139.
6. Crimmins, M. T. New development in the enantioselective synthesis of cyclopentyl carbocyclic nucleosides. Tetrahedron 1998, 54, 9229-9272.
7. Choi, Y.; Lee, K.; Hong, J. H.; Schinazi, R. F.; Chu, C. K. Synthesis and anti-HIV activity of L-2′-fluoro-2′,3′-unsaturated purine nucleosides. Tetrahedron Lett. 1998, 39, 4437-4440.
8. Lee, K.; Choi, Y.; Gullen, E.; Schlueter-Wirtz, S.; Schinazi, R. F.; Cheng, Y.-C.; Chu, C. K. Synthesis and anti-HIV and anti-HBV activities of 2′-fluoro-2′,3′-unsaturated L-nucleosides. J. Med. Chem. 1999, 42, 1320-1328.
9. Lee, K.; Choi, Y.; Gumina, G.; Zhou, W.; Schinazi, R. F.; Chu, C. K. Structure-activity relationships of 2′-fluoro-2′,3′- unsaturated D-nucleosides as anti-HIV agents. J. Med. Chem. 2002, 45, 1313-1320.
10. Chong, Y.; Choo, H.; Choi, Y.; Mathew, J.; Schinazi, R. F.; Chu, C. K. Stereoselective synthesis and antiviral activity of D-2′, 3′-didehydro-2′,3′-dideoxy-2′-fluoro-4′- thionucleosides. J. Med. Chem. 2002, 45, 4888-4898.
11. Choo, H.; Chong, Y.; Choi, Y.; Mathew, J.; Schinazi, R. F.; Chu, C. K. Synthesis, anti-HIV activity and molecular mechanism of drug resistance of L-2′,3′-didehydro-2′,3′-dideoxy-2′- fluoro-4′-thionucleosides. J. Med. Chem. 2003, 46, 389-398.
12. Zhu, W.; Chong, Y.; Choo, H.; Mathews, J.; Schinazi, R. F.; Chu, C. K. Synthesis, structure-activity relationships, and mechanism of drag resistance of D- and L-β-3′-fluoro-2′,3′- unsaturated-4′-thionucleosides as anti-HIV agents. J. Med. Chem. 2004, 47, 1631-1640.
13. Zhou, W.; Gumina, G.; Chong, Y.; Wang, J.: Schinazi, R. F.; Chu, C. K. Synthesis, structure-Activity relationships and drug resistance of β-L-3′-fluoro-2′,3′-unsaturated nucleosides as anti-HIV agents. J. Med Chem. 2004, 47, 3399-3408.
14. Wang, J.; Jin, Y. H.; Rapp, K. L.; Bennett, M.; Schinazi, R. F.; Chu, C. K. Synthesis, antiviral activity and mechanism of drag resistance of D- and L-2′,3′-didehydro-2′,3′-dideoxy-2′- fluoro-carbocyclic nucleosides. J. Med. Chem. 2005, 48, 3736-3748.
15. Shealy, Y. F.; O'Dell, C. A.; Thorpe, M. C. carbocyclic analogues of thymidine nucleosides and related 1-substituted thymines. J. Heterocycl. Chem. 1981, 18, 383-389.
16. Shealy, Y. F.; O'Dell, C. A. Synthesis of the carbocyclic analogues of uracil nucleosides. J. Heterocycl. Chem. 1976, 13, 1015-1020.
17. Polpin, E. A.; Corbett, T.; Flaherty, L.; Tarasoff, P.; Redman, B. G.; Valdivieso, M.; Baker, L. Difluorodeoxycytidine (dFdC, gemcitabine): A phase I study. Invest. New Drugs 1992, 10, 165-170.
18. Schinazi, R. F.; Lloyd, R. M. Jr.; Nguyen, M.-H.; Cannon, D. L.; McMillan, A.; Ilksoy, N.; Chu, C. K.; Liotta, D. C.; Bazmi, H. Z.; Mellors, J. W. Characterization human immunodeficiency viruses resistant to oxthiolane-cytosine nucleosides. Antimicrob. Agents. Chemother. 1993, 37, 875-881.
19. Naeger, L. K.; Margot, N. A.; Miller, M. D.: Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antiviral Res. 2001, 6, 115-126.
20. (a) Gao, H.; Boyer, P. L.; Sarafianos, S. G.; Arnold, E.; Hughes, S. H. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J. Mol. Biol. 2000, 300, 403-418.
21. (b) Schinazi, R. F.; Schlueter-Wirtz, S.; Stuyver, L. Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. Antimicrob. Agents. Chemother. 2001, 12 (Suppl. 1), 61-65.
22. Vince, R.; Hua, M.; Brownell, J.; Daluge, S.; Fangchen, Lee.; Shannon, W. M.; Lavelle, G. C.; Quails, J.; Weislow, O. S.; Kiser, R.; Canonico, P. G.; Schultz, R. H.; Narayanan, V. L.; Mayo, J. G.; Shoemaker, R. H.; Boyd, M. R. Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. Biochem. Biophys. Res. Commun. 1988, 156, 1046-1053.
23. Smith, M. S.; Kessler, J. A.; Rankin, C. D.; Pagano, J. S.; Kurtzberg, J.; Carter, S, G. Evaluation of synergy between carbovir and 3′-azido-2′,3′-deoxythymidine for inhibition of human immunodeficiency virus type 1. Antimicrob. Agents. Chemother. 1993, 37, 144-147.
24. Daluge, S. M.; Good, S. S.; Faletto, M. B.; Miller, W. H.; St. Clair, M. H.; Boone, L. R.; Tisdale, M.; Parry, N. R.; Reardon, J. E.; Dornsife, R. E.; Averett, D. R.; Krenitsky, T. A. 1592U89, a novel carbocyclic nucleoside analog with potent selective anti-human immunodeficiency virus activity. Antimicrob. Agents. Chemother. 1997, 41, 1082-1093.
25. Harrigan, P. R.; Stone, C.; Griffin, P.; Najera, I.; Bloor, S.; Kemp, S.; Tisdale, M.; Larder, B. Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. J. Infect. Dis. 2000, 181, 912-920.
26. Tisdale, M.; Alnadaf, T.; Cousens, D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob. Agents. Chemother. 1997, 41, 1094-1098.
27. Ray, A. S.; Yang, Z.; Shi, J.; Hobbs, A.; Schinazi, R. F.; Chu, C. K.; Anderson, K. S. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate. Biochemistry 2002, 41, 5150-5162.
28. Sarafinos, S. G.; Das, K.; Clark, JR. A. D.; Ding, J.; Boyer, P. L.; Hughes, S. H.; Arnold, E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 10027-10032.
29. Schinazi, R. F.; Sommadossi, J. P.; Saalmann, V.; Cannon, D. L.; Xie, M. Y.; Hart, G. C.; Hahn, E. F. Activity of 3′-azido-3′-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1. Antimicrob. Agents. Chemother. 1990, 34, 1061-1067.
30. Stuyer, L. J.; Lostia, S.; Adams, M.; Mathew, J. S.; Pai, B. S.; Tharnish, P. M.; Choi, Y.; Chong, Y.; Choo, H.; Chu, C. K.; Otto, M. J.; Schinazi, R. F. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents. Chemother. 2002, 46, 3854-2860.
31. Huang, H.; Chopra, R.; Verdine, G. L.; Harrison, S. C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance. Science 1998, 282, 1669-1675.
32. (a) Cornell, W. D.; Cieplak, P.; Bayly, C. I.; Gould, I. R.; Merz, K. M.; Ferguson, D. M.; Spellmeyer, D. C.; Fox, T.; Caldwell, J. W.; Kollman, P. A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 1995, 117, 5179-5197.
33. (b) http://www.amber.uscf.edu/amber/Questions/fluorine.html.
34. Dunitz, J. D.; Taylor, R. Organic fluorine hardly ever accepts hydrogen bonds. Chem. Eur. J. 1997, 3, 89-98.